Rapport Therapeutics (RAPP) closed at $26.07 on November 9, 2026, up 6.7% from the previous close, on volume of 748,164 shares (30-day average 1,132,206).
Data as of November 9, 2026.
9-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Calendar Put Ladder with Ratio | 20-Nov-2620[2x] : 32.5[2x] P|18-Dec-2640 P | 4,185 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Thu, 5-Nov 7:20 AM ET)
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from H.C. Wainwright
TipRanks (Thu, 5-Nov 6:36 AM ET)
Analysts’ Top NA Picks: Figma, Inc. Class A (FIG), Chime Financial, Inc. Class A (CHYM)
TipRanks (Thu, 5-Nov 6:10 AM ET)
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Market Chameleon (Mon, 2-Nov 3:20 AM ET)
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
RAPP rallies as Rapport prices $175M stock deal and sets $26.78 convertible conversion price
Market Chameleon (Thu, 29-Oct 7:44 AM ET)
Globe Newswire (Wed, 28-Oct 6:00 AM ET)
Globe Newswire (Tue, 27-Oct 4:32 PM ET)
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Rapport Therapeutics trades on the NASDAQ stock market under the symbol RAPP.
As of November 9, 2026, RAPP stock price climbed to $26.07 with 748,164 million shares trading.
RAPP has a beta of 1.69, meaning it tends to be more sensitive to market movements. RAPP has a correlation of 0.18 to the broad based SPY ETF.
RAPP has a market cap of $1.55 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that RAPP belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
RAPP has underperformed the market in the last year with a return of +2.8%, while the SPY ETF gained +13.4%. In the last 3 month period, RAPP fell short of the market, returning -43.8%, while SPY returned -1.8%. However, in the most recent 2 weeks RAPP has outperformed the stock market by returning +0.5%, while SPY returned -1.0%.
RAPP support price is $23.13 and resistance is $25.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPP shares will trade within this expected range on the day.
